News
-
-
PRESS RELEASE
GameSquare Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
GameSquare Holdings, Inc. receives Nasdaq approval for bid price extension until September 7, 2026. Company planning necessary actions to regain compliance with Nasdaq listing requirements -
-
PRESS RELEASE
Wolftank Group successfully completes hydrogen infrastructure order for TPER – second refueling station in Bologna finalized
Wolftank Group completes hydrogen infrastructure project for TPER, enabling zero-emission mobility in public transport with state-of-the-art technology. Project delivered on schedule -
PRESS RELEASE
Algo Grande Identifies Additional Skarn Mineralization 3km South of Cerro Grande, With Samples Above 3% Copper and Confirms Copper in Multiple Targets on the Property
Algo Grande Copper Corp. provides exploration update on its Adelita Project in Mexico, confirming extensive mineralization with high-grade copper, gold, and silver. New skarn zone discovered -
PRESS RELEASE
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases
Revive Therapeutics announces key patent milestones for Bucillamine in medical countermeasures and infectious diseases, strengthening its strategic position -
-
-
PRESS RELEASE
Kasowitz LLP Publishes an Updated Report Examining the Fundamental Due Process Defects Underlying the Continued Detention and Prosecution of Erion Veliaj, the Mayor of Tirana, Albania
Kasowitz LLP releases an updated report on due process defects in Mayor Veliaj's detention and prosecution in Tirana, Albania, highlighting SPAK's conduct and the need for intervention by the American government -
PRESS RELEASE
WHO Foundation and Novo Nordisk Expand Collaboration to Provide Financial Support towards strengthening health systems for Cardio-Renal-Metabolic Diseases
WHO Foundation and Novo Nordisk expand collaboration to strengthen health systems for Cardio-Renal-Metabolic Diseases, with Novo Nordisk committing USD 7.9 million
